mardi 11 juin 2019

Onco Actu du 11 juin 2019


1. BIOLOGIE



Study finds macrophages’ pathway to nurture PTEN-deficient glioblastoma [MD Anderson Cancer Center]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Taking Aim at Tobacco: Highlights From Annual Meeting Symposium [Cancer Research Catalyst]










U.S. FDA warns flavored e-cigarette makers over social media posts [Reuters]











4.1 DÉP., DIAG. & PRONO. - PROSTATE



Prostate cancer screening scan hope [BBC News]











MRI scans to be trialled as test for prostate cancer [The Guardian]










4.10 DÉP., DIAG. & PRONO. - POUMON



Roche launches first in vitro lung cancer diagnostic test [Pharma Times]











4.15 DÉP., DIAG. & PRONO. - IMAGERIE



New Radiotracer Can Identify Nearly 30 Types of Cancer [SNMMI]











I face a known risk from cancer and an undetermined risk from the scan used to detect it. Which is worse? [Washington Post]











5.10 TRAITEMENTS - ESSAIS



Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer [NCI]











5.12.10 IMMUNOTHÉRAPIES - FUSIONS ET ACQUISITIONS



Merck inks $773M Tilos takeout to bag TGFβ cancer programs [Fierce Biotech]











Merck to buy private Tilos in deal worth up to $773M [Biopharma Dive]










Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal [Xconomy]











Merck to Acquire Tilos Therapeutics [Merck]











Merck makes a $773M bet on TGFβ, acquiring a three-year-old biotech [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



New Center for Proton Therapy Opens in Manhattan [Memorial Sloan Kettering Cancer Center]











Study: Radiation drives up cardiac event risk for lung cancer patients [UPI]











Proton therapy: Cancer revolution or costly white elephant? [The Spectator]










5.2 PHARMA



Servier, armed with Shire cancer drugs, builds out vision for U.S. future [Fierce Pharma]











5.2.3 PHARMA - ÉCONOMIE



The top 20 highest-paid biopharma CEOs of 2018 [Fierce Pharma]











Sticking to hottest trends in biopharma, Oncologie gathers $80M for next leg of trans-Pacific clinical journey [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA [Seattle Genetics]











Roche snags first-in-class FDA nod for lymphoma drug Polivy [Fierce Pharma]











FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma [Roche]











In a boost to Rituxan franchise, Roche nabs quick approval for polatuzumab vedotin [EndPoints]











Roche's combo lymphoma treatment wins U.S. FDA approval [Reuters]











FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma [FDA]










6.1 OBSERVATION



Body Fat Distribution Linked to Higher Risk of Aggressive Prostate Cancer [Wiley]










6.10 POLITIQUES



Not playing NICE: UK drugs gatekeeper in US crosshairs [Politico]










6.7 DMP, BIG DATA & APPLIS



Digital health and the elusive quest for cost savings [Lancet Digital Health]










6.7.3 DMP



Lost in translation: Epic goes to Denmark [Politico]











6.8 COMMUNICATION



The social dynamics of lung cancer talk on Twitter, Facebook and Macmillan.org.uk [Npj Digital Medicine]